Contributing Member of the Healthcare Councils

GLG News by this Author

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

It will cost moe tim and Money Dealing with China

October 6, 2008

Analysis of:Pharma's new favorite outsourcing spot: China | www.fiercepharma.com

Rising costs in China makes it less attractive Increased regulatory oversight will increase cost and in the long run improve quality Will all of the problems in China result in better products for both the global market and China  or just for the exports?

Improving the Quality of Life while living in our means

August 12, 2008

Analysis of:UK Says Kidney Cancer Drugs Are Too Pricey | www.pharmalot.com

Shorten the Approval process Increase the market exclusivity Implement New Technology

looking to the future

June 4, 2008

Analysis of:Mylan Inc. Acquires Central Eastern European Generics Businesses of Merck KGaA | www.pipelinereview.com

Mylan is positioned for growth in developing markets They have developed a presence in markets that they will need to have access to to compete with the Teva's and Sandoz's of the world Outlet for the older products that Mylan offers as the develop newer products for the more established market places. Potential access to low cost drugs as well

Do not forget the cost of supplying from China

May 27, 2008

Analysis of:China Muscles In On The Generics Industry | www.pharmalot.com

With the recent scandals around quality, one needs to look at China's government stepping in and improving the quality. Expect additional testing requirements and regulatory requirements consider the added cost of companies sending QA teams into China to support their development

China-not your low cost center any longer

May 27, 2008

Analysis of:China Muscles In On The Generics Industry | www.pharmalot.com

Cost of goods in China are increasing dramatically over the last few years The cost of compliance has and will increase dramatically as well. The internal regulatory costs for compliance has increased as well. Working with China is not cheap and we should look at China more as a part of a strategic sourcing plan and not as a cheap cost of goods center.

Active Pharmaceutical Ingredients Producers Follow the Move to China

June 18, 2007

Analysis of:Drug Sales Predicted to Double to $1.3 Trillion by 2020 | www.therapeuticsdaily.com

Chemical and Pharmaceutical Solutions, Inc has already seen a  shift in the research, development and production of pharmaceuticals to China. Several reports estimate that by 2010, they will rank in the top ten globally. With the return of people to China, aging population and the medical insurance industry evolves, we expect to see increased drug usage.  Most companies have  established a foothold in China and this trend will continue. Today, we see a number of the support companies  establishing joint ventures, partnerships or their own facilities. This includes the producers of the high tech process equipment, including fermentation and biological systems.  today, we can expect to see process equipment equal to the west. Clinical Testing labs have also established themselves in China and the estimates for the development of a new drugs in China could be less that $10 million US. This could make it easier to launch drugs in China first. Technology is also no loner

Active Pharmaceutical Ingredients Producers Follow the Move to China

June 18, 2007

Analysis of:Drug Sales Predicted to Double to $1.3 Trillion by 2020 | www.therapeuticsdaily.com

Chemical and Pharmaceutical Solutions, Inc has already seen a  shift in the research, development and production of pharmaceuticals to China. Several reports estimate that by 2010, they will rank in the top ten globally. With the return of people to China, aging population and the medical insurance industry evolves, we expect to see increased drug usage.  Most companies have  established a foothold in China and this trend will continue. Today, we see a number of the support companies  establishing joint ventures, partnerships or their own facilities. This includes the producers of the high tech process equipment, including fermentation and biological systems.  today, we can expect to see process equipment equal to the west. Clinical Testing labs have also established themselves in China and the estimates for the development of a new drugs in China could be less that $10 million US. This could make it easier to launch drugs in China first. Technology is also no loner

Page : 11 to 7 of 7